drugset / Trial / NCT05207514
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase III Clinical Trial to Compare the Efficacy and the Safety of AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Taxotere Versus AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Nanoxel M as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Timeline
- Start
- 2022-03-31
- Primary completion
- 2024-02-07
- Completion
- 2024-05-09
Outcome
Outcome not reported
Stopped (Enrollment): “The Decision to Terminate Early Due to Difficulties in Recruiting Participants and Conducting the Study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |